Relationship between platelet activation and low cAMP levels in patients with aPL+. (A) Estimation of cAMP in platelets (2 × 105/μL) purified from the fresh blood of healthy controls (n = 20), patients who are aPL+ (n = 38), and patients with aPL-negative VTE [VTE (aPL−), n = 8]. (B) Flow cytometric evaluation of platelet surface P selectin (CD62P+ events within the CD41+ population) and (C) activated αIIbβ3 receptor (PAC-1+ events within the CD41+ population) in fresh blood. (D) ELISA-based estimation of plasma PF4. Spearman correlation for platelet cAMP of aPL+ patients with surface CD62P (E), activated αIIbβ3 receptor (F), plasma PF4 (G), and anti-PS/PT IgG (H). Data represent mean ± standard deviation (SD). ∗P < .05, ∗∗P < .01, ∗∗∗∗P < .0001, and nonsignificant (ns) by 1-way analysis of variance (ANOVA) with the Tukey multiple comparisons correction. MFI, Mean Fluorescence Intensity.
Figure 1.

Relationship between platelet activation and low cAMP levels in patients with aPL+. (A) Estimation of cAMP in platelets (2 × 105/μL) purified from the fresh blood of healthy controls (n = 20), patients who are aPL+ (n = 38), and patients with aPL-negative VTE [VTE (aPL−), n = 8]. (B) Flow cytometric evaluation of platelet surface P selectin (CD62P+ events within the CD41+ population) and (C) activated αIIbβ3 receptor (PAC-1+ events within the CD41+ population) in fresh blood. (D) ELISA-based estimation of plasma PF4. Spearman correlation for platelet cAMP of aPL+ patients with surface CD62P (E), activated αIIbβ3 receptor (F), plasma PF4 (G), and anti-PS/PT IgG (H). Data represent mean ± standard deviation (SD). ∗P < .05, ∗∗P < .01, ∗∗∗∗P < .0001, and nonsignificant (ns) by 1-way analysis of variance (ANOVA) with the Tukey multiple comparisons correction. MFI, Mean Fluorescence Intensity.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal